Veterinary Medicines

VANGUARD CPV-L.

Authorised
  • Canine parvovirus, strain NL-35-D, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
Download as PDF

Product identification

Medicine name:
VANGUARD CPV-L.
Active substance:
  • Canine parvovirus, strain NL-35-D, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, strain NL-35-D, Live
    316228000.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    40.00
    unit(s)
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    40.00
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Available in:
  • Ireland
Package description:
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 100vials of 1 ml liquid VanguardCPV-L.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 25vials of 1 ml liquid VanguardCPV-L.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 10vials of 1 ml liquid VanguardCPV-L.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 1vial of 1 ml liquid VanguardCPV-L.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10387/084/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."